# Energenesis Biomedical and Yoo Young Pharm Sign MOU for ENERGI-F703DFU Development and Commercialization in Korea

- Link: https://www.thailand-business-news.com/pr-news/energenesis-biomedical-and-yoo-young-pharm-sign-mou-for-energi-f703dfu-development-and-commercialization-in-korea
- Published: 2026-10-05T17:00:00+07:00
- Author: PR Newswire

TAIPEI, Oct. 5, 2026 /PRNewswire/ — Energenesis Biomedical Co., Ltd. (TWSE: 6657)
today announced that it has signed a Memorandum of Understanding ("MOU") with Yoo
Young Pharm. Co., Ltd. ("YYP"), a South Korea-based pharmaceutical company, to explore
a collaboration for the development, registration, and commercialization of ENERGI-
F703DFU in Korea.

Under the MOU, the parties intend to work toward a definitive agreement under which
YYP would receive rights to develop, register, and commercialize ENERGI-F703DFU 
in Korea, drawing on Energenesis’ data package — including Phase III clinical trial
data — together with YYP’s commercial and clinical network in the region. The MOU
establishes the framework for continued discussions; terms of any definitive agreement
remain subject to further negotiation between the parties.

**About ENERGI-F703DFU**

ENERGI-F703DFU is an investigational topical small-molecule gel designed to promote
healing of diabetic foot ulcers by modulating cellular energy pathways. The drug
candidate is intended to increase intracellular ATP levels at the wound site, support
epithelial cell migration and activate intrinsic repair mechanisms.

In a post-hoc analysis of the Phase II study (NCT02672436), patients meeting the
current Phase III eligibility criteria achieved complete wound closure rates of 
36.7% with ENERGI-F703DFU versus 9.1% with vehicle control over a 12-week treatment
period (P<0.05).

**About Energenesis Biomedical**

Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a clinical-stage biopharmaceutical
company dedicated to developing innovative therapeutics that restore cellular energy
and activate intrinsic repair mechanisms. The Company combines proprietary small-
molecule innovation with AI-driven drug repurposing to address significant unmet
medical needs across multiple therapeutic areas, including chronic wounds, neurodegenerative
diseases, and rare disorders.

**About Yoo Young Pharm. Co., Ltd.**

Established in 1981, Yoo Young Pharm. Co., Ltd. is a fully integrated South Korean
pharmaceutical company with comprehensive capabilities spanning in-house R&D, global
cGMP-compliant manufacturing (PIC/S, PMDA), and commercialization. The Company leverages
established leadership in musculoskeletal care, metabolic diseases, and tissue regeneration
to advance innovative therapeutics and deliver high-quality healthcare solutions
across domestic and global markets. For more information, please visit [www.yypharm.co.kr](https://www.yypharm.co.kr).

**Forward-Looking Statements**

This press release contains forward-looking statements regarding the potential collaboration
between Energenesis Biomedical and Yoo Young Pharm, including statements about ongoing
clinical development and future licensing discussions. These statements involve 
risks and uncertainties, and actual results may differ materially. Energenesis Biomedical
undertakes no obligation to update these statements except as required by law. For
more information, please visit [www.energenesis-biomedical.com](http://www.energenesis-biomedical.com/).

**Media & Business Development Contact**

Business Development Team
Energenesis Biomedical Co., Ltd.Email: [**partnership@energenesis-biomedical.com**](https://www.thailand-business-news.com/pr-news/partnership@energenesis-biomedical.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Energenesis Biomedical and Yoo Young Pharm Sign MOU for ENERGI-F703DFU Development and Commercialization in Korea ](http://www.prnasia.com/story/archive/5063455_HK63455_0?rand=184833)